Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

NCT01108341 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT01108341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01108341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
Lead sponsor
Cephalon
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2010
Completion date
October 31, 2011
Enrollment
50 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma (nhl)